Replies to post #882 on Idenix Pharmaceuticals (IDIX)

[go seek]

1Q07 Hepsera sales were $71.3M ($285M annualized), +35% year-over-year

wow! 35% year over year even w/ Baraclude in the mix...
if anything, i thot Hepsera sales would fall off some.

aren't you surprised by the +35% year-over-year, +8% quarter-over-quarter?

Haven't researched recent sales figures for Baraclude... but one would expect good sales growth.

researched...
Sales for BARACLUDE were $36M, this recently launched product continued to gain market share.

[DewDiligence]

1Q07 Baraclude sales: $45M, +309% vs 1Q06, +25% vs 4Q06.

http://biz.yahoo.com/prnews/070426/nyth060.html?.v=89

Combined sales of Baraclude and Hepsera in 1Q07 were $116M, +81% vs 1Q06, +18% vs 4Q06.

Obviously, the overall HBV market is growing by leaps and bounds.